ASCO Highlights

Researchers in the ADJUBIL study plan to assess the clinical activity of the immunotherapies durvalumab and tremelimumab with or without capecitabine in patients with resectable biliary tract cancer in the adjuvant setting.

Basket study investigated targeted therapies as second-line treatment for patients with biliary tract cancer who are HER2-positive.

Researchers are investigating novel combination therapies, including immunotherapies and poly-ADP ribose polymerase (PARP) inhibitors, to improve survival in patients with biliary tract cancer; here, the BilT-02 study is summarized.

Preliminary results from the phase 2b HERIZON-BTC-01 study investigating the efficacy of zanidatamab in patients with HER2-positive biliary tract cancer are presented.

A subanalysis of the STAMP trial examines the clinical impact of using circulating tumor DNA for detecting molecular residual disease and monitoring in patients with CCA in the adjuvant setting.

The researchers found that EGFR amplifications and FGFR3 fusions may be important predictive biomarkers in biliary tract cancer (BTC) and may serve as a future target for systemic anticancer therapy in patients with BTC.

Pashtoon Kasi, MD, MS, presented results of a study exploring the utility of circulating tumor DNA–based comprehensive genomic profiling to detect actionable rearrangements in patients with gastrointestinal malignancies.

Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.